Avalyn Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	92.31	52.32	23.96
Short-Term Investments	30.82	86.09	86.68
Cash & Short-Term Investments	123.13	138.41	110.63
Cash Growth	-	25.11%	-
Other Receivables	0.25	0.54	0.59
Receivables	0.25	0.54	0.59
Prepaid Expenses	0.86	0.71	0.31
Other Current Assets	5.74	3.91	2.86
Total Current Assets	129.99	143.56	114.39
Property, Plant & Equipment	2.68	2.32	0.09
Long-Term Investments	-	-	7.49
Other Long-Term Assets	3	3	2.55
Total Assets	135.66	148.88	124.52
Accounts Payable	3.15	3.76	2.28
Accrued Expenses	8.13	9.89	6.47
Current Portion of Leases	0.51	0.44	-
Total Current Liabilities	11.79	14.09	8.74
Long-Term Leases	1.09	1.23	-
Total Liabilities	27.69	15.32	8.74
Common Stock	0.02	0.02	0.01
Additional Paid-In Capital	27.95	26.55	5.43
Retained Earnings	-292.23	-265.36	-180.16
Comprehensive Income & Other	0.01	0.13	0.2
Total Common Equity	-264.25	-238.66	-174.52
Shareholders' Equity	107.98	133.57	115.78
Total Liabilities & Equity	135.66	148.88	124.52
Total Debt	16.41	1.67	-
Net Cash (Debt)	106.72	136.74	118.12
Net Cash Growth	-	15.76%	-
Net Cash Per Share	88.23	140.82	437.25
Filing Date Shares Outstanding	44.33	1.23	0.28
Total Common Shares Outstanding	1.23	1.23	0.28
Working Capital	118.2	129.47	105.64
Book Value Per Share	-214.41	-194.47	-630.46
Tangible Book Value	-264.25	-238.66	-174.52
Tangible Book Value Per Share	-214.41	-194.47	-630.46
Machinery	0.43	0.16	0.11
Construction In Progress	0.01	0.68	-

SEC Filings: 10-K · 10-Q